StockDuty ← Dashboard Nov 06, 2026 03:36 PM ET
SignalCorporate

RenovoRx maintains $3.75M-$4.25M 2026 revenue guidance as it targets 36 active cancer centers

RenovoRx reaffirmed $3.75M-$4.25M 2026 revenue guidance targeting 36 active cancer centers.

What changed
RenovoRx reaffirmed $3.75M-$4.25M 2026 revenue guidance targeting 36 active cancer centers.
Why it matters
RenovoRx reaffirmed $3.75M-$4.25M 2026 revenue guidance targeting 36 active cancer centers. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →